Statements (26)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:immunotherapy
|
gptkbp:bioavailability |
high
|
gptkbp:casnumber |
1207450-10-9
|
gptkbp:chemical_formula |
C18 H22 N4 O5 S
|
gptkbp:clinical_trial |
Phase 1
|
gptkbp:composed_by |
gptkb:chemical_compound
|
gptkbp:developed_by |
gptkb:Gilead_Sciences
|
gptkbp:dissolved |
water-soluble
|
gptkbp:first_described_by |
gptkb:2014
|
https://www.w3.org/2000/01/rdf-schema#label |
Galidesivir
|
gptkbp:invention |
patented
|
gptkbp:mechanism_of_action |
inhibits viral RNA polymerase
|
gptkbp:related_to |
gptkb:Marburg_virus
gptkb:Hantavirus gptkb:Nipah_virus gptkb:Ebola_virus |
gptkbp:research_focus |
emerging infectious diseases
|
gptkbp:route_of_administration |
intravenous
|
gptkbp:side_effect |
fatigue
headache nausea diarrhea |
gptkbp:targets |
RNA viruses
|
gptkbp:used_for |
treatment of viral infections
|
gptkbp:bfsParent |
gptkb:Bio_Cryst_Pharmaceuticals
|
gptkbp:bfsLayer |
7
|